ALK
Test Description
Anaplastic Lymphoma Kinase (ALK) immunohistochemistry is a qualitative assay to identify patients who are eligible for treatment with XALKORI® (crizotinib), ZYKADIA® (ceritinib), ALECENSA® (alectinib) or LORBRENA® (lorlatinib).
Indicated treatment:
- XALKORI® (crizotinib) for ALK-positive metastatic NSCLC and other kinases
- ZYKADIA® (ceritinib) for ALK-positive metastatic NSCLC who have had no previous treatment, or who have progressed on, or who are intolerant to, crizotinib
- ALECENSA® (alectinib) for ALK-positive metastatic NSCLC who have had no previous treatment, or who have progressed on, or who are intolerant to, crizotinib
- LORBRENA® (lorlatinib) for ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease
Ordering Information
Test Code: LLK
System: VENTANA
Turnaround Time: 3 – 5 working days, upon sample receipt
Accepted Specimens:
- FFPE Tissue/Cell Blocks
- FFPE Slides
Refer to Specimen Requirements for more information.